SkyePharma To Jettison Its Injectables Business
This article was originally published in The Pink Sheet Daily
The firm will use proceeds from the divestiture to develop its oral and pulmonary products, including the pipeline asthma therapy Flutiform.
You may also be interested in...
U.K.-based firms both have expertise in pulmonary delivery systems.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.